BioSante Pharmaceuticals, Inc. to Present at Jefferies Global Healthcare Conference
LINCOLNSHIRE, Illinois (June 4, 2012) – BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced today announced that Stephen M. Simes, BioSanteâ€™s president & CEO will present a corporate update at the Jefferies 2012 Global Healthcare Conference in New York on June 6, 2012 at 11:00 am EDT.
Mr. Simes will provide an overview of BioSante, as well as an update on the LibiGel® (testosterone gel) Phase III clinical development program, and a review of published results using BioSante´s GVAX Cancer Immunotherapies in combination with ipilimumab (Ipi; Yervoy; BMS).
A live audio webcast of remarks by Mr. Simes may be accessed. The webcast will be archived for 90 days.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante´s products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development. BioSante also is developing a portfolio of cancer vaccines, with 17 Phase I and Phase II clinical trials currently on-going. Four of these vaccines have been granted Orphan Drug designation by the U.S.
Food and Drug Administration (FDA). BioSante´s other products include a testosterone gel for male hypogonadism, which is licensed to Teva Pharmaceuticals USA, Inc., and for which a New Drug Application (NDA) was approved by the FDA in February 2012, and the Pill-Plus™, an oral contraceptive in Phase II clinical development by Pantarhei Bioscience B.V. BioSante´s first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, is marketed in the U.S. by Jazz Pharmaceuticals, BioSante´s licensee. Additional information is available online at: biosantepharma.cdmail.biz.
For more information please contact:
Harris D. McKinney, Inc.
The Trout Group LLC